Neurocrine Biosciences (NBIX) Releases Quarterly Earnings Results, Misses Expectations By $0.11 EPS

Neurocrine Biosciences (NASDAQ:NBIX) released its quarterly earnings data on Tuesday. The company reported $0.07 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.18 by ($0.11), Bloomberg Earnings reports. The firm had revenue of $94.52 million for the quarter, compared to analysts’ expectations of $94.00 million. During the same quarter in the prior year, the firm posted ($0.51) EPS.

Shares of Neurocrine Biosciences (NASDAQ NBIX) opened at $85.38 on Thursday. Neurocrine Biosciences has a 1 year low of $39.21 and a 1 year high of $91.82. The company has a quick ratio of 14.37, a current ratio of 14.38 and a debt-to-equity ratio of 1.05.

In other Neurocrine Biosciences news, CEO Kevin Charles Gorman sold 3,750 shares of the business’s stock in a transaction on Tuesday, January 16th. The shares were sold at an average price of $78.89, for a total transaction of $295,837.50. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, insider Darin Lippoldt sold 6,279 shares of the business’s stock in a transaction on Monday, December 4th. The shares were sold at an average price of $75.04, for a total transaction of $471,176.16. Following the transaction, the insider now owns 19,436 shares in the company, valued at approximately $1,458,477.44. The disclosure for this sale can be found here. Insiders sold 337,950 shares of company stock worth $26,613,876 in the last 90 days. 4.80% of the stock is currently owned by company insiders.

An institutional investor recently raised its position in Neurocrine Biosciences stock. The Manufacturers Life Insurance Company raised its position in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 7.8% during the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 2,665 shares of the company’s stock after acquiring an additional 193 shares during the period. The Manufacturers Life Insurance Company ‘s holdings in Neurocrine Biosciences were worth $123,000 as of its most recent filing with the Securities & Exchange Commission.

Several research firms have recently issued reports on NBIX. Oppenheimer set a $100.00 price objective on shares of Neurocrine Biosciences and gave the company a “buy” rating in a research report on Wednesday. Deutsche Bank lifted their price objective on shares of Neurocrine Biosciences to $97.00 and gave the company a “buy” rating in a research report on Wednesday. Barclays reiterated an “overweight” rating and set a $100.00 price objective on shares of Neurocrine Biosciences in a research report on Wednesday. JPMorgan Chase & Co. lifted their price objective on shares of Neurocrine Biosciences from $79.00 to $100.00 and gave the company an “overweight” rating in a research report on Wednesday. Finally, BidaskClub upgraded shares of Neurocrine Biosciences from a “buy” rating to a “strong-buy” rating in a research report on Wednesday, January 31st. One research analyst has rated the stock with a hold rating, fifteen have assigned a buy rating and one has assigned a strong buy rating to the stock. Neurocrine Biosciences has a consensus rating of “Buy” and an average target price of $89.53.

COPYRIGHT VIOLATION NOTICE: This piece was posted by Week Herald and is owned by of Week Herald. If you are reading this piece on another website, it was stolen and republished in violation of United States & international copyright legislation. The legal version of this piece can be accessed at https://weekherald.com/2018/02/15/neurocrine-biosciences-nbix-releases-quarterly-earnings-results-misses-expectations-by-0-11-eps.html.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc is engaged in discovering and developing pharmaceuticals, in diseases with unmet medical needs, through its research and development (R&D) platform, focused on neurological and endocrine based diseases and disorders. Its three lead late-stage clinical programs are elagolix, which is a gonadotropin-releasing hormone (GnRH) antagonist for endometriosis and uterine fibroids; INGREZZA (valbenazine), which is a vesicular monoamine transporter 2 (VMAT2) inhibitor, for the treatment of movement disorders, and opicapone, which is a selective catechol-O-methyltransferase inhibitor that is an adjunct therapy to preparations of levodopa/Dihydroxyphenylalanine (DOPA) decarboxylase inhibitors for adult patients with Parkinson’s disease.

Earnings History for Neurocrine Biosciences (NASDAQ:NBIX)

Receive News & Ratings for Neurocrine Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply